Description: Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
Home Page: www.lysogene.com
18-20 rue Jacques Dulud
Neuilly-sur-Seine,
92200
France
Phone:
33 1 41 43 03 90
Officers
| Name | Title |
|---|---|
| Ms. Karen Pignet-Aiach MBA | Founder, Chairman & CEO |
| Mr. Stephane Durant des Aulnois | Admin. & Financial Director |
| Dr. Ralph Laufer | Chief Scientific Officer |
| Dr. Michaël Hocquemiller Ph.D. | Head of Non-Clinical Devel. |
| Dr. Marie Deneux | Chief Regulatory affairs |
| Dr. Marie Trad | Chief Clinical Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.71 |
| Price-to-Sales TTM: | 0.8631 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |